Esperion Therapeutics (ESPR) Gross Margin (2020 - 2025)
Historic Gross Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 52.71%.
- Esperion Therapeutics' Gross Margin fell 138100.0% to 52.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 58.2%, marking a year-over-year decrease of 233800.0%. This contributed to the annual value of 79.36% for FY2024, which is 165500.0% up from last year.
- Esperion Therapeutics' Gross Margin amounted to 52.71% in Q3 2025, which was down 138100.0% from 65.35% recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Gross Margin registered a high of 95.57% during Q2 2021, and its lowest value of 51.3% during Q2 2022.
- Moreover, its 5-year median value for Gross Margin was 65.35% (2025), whereas its average is 67.38%.
- As far as peak fluctuations go, Esperion Therapeutics' Gross Margin crashed by -442800bps in 2022, and later skyrocketed by 405800bps in 2024.
- Esperion Therapeutics' Gross Margin (Quarter) stood at 67.05% in 2021, then increased by 16bps to 77.89% in 2022, then fell by -17bps to 64.49% in 2023, then dropped by -2bps to 62.91% in 2024, then fell by -16bps to 52.71% in 2025.
- Its Gross Margin stands at 52.71% for Q3 2025, versus 65.35% for Q2 2025 and 51.48% for Q1 2025.